Parkside Financial Bank & Trust Has $460,000 Stock Position in Lam Research Co. (NASDAQ:LRCX)

Parkside Financial Bank & Trust boosted its holdings in shares of Lam Research Co. (NASDAQ:LRCX) by 13.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 587 shares of the semiconductor company’s stock after buying an additional 68 shares during the period. Parkside Financial Bank & Trust’s holdings in Lam Research were worth $460,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Orion Capital Management LLC bought a new stake in Lam Research during the 3rd quarter valued at approximately $25,000. BluePath Capital Management LLC bought a new stake in Lam Research during the 3rd quarter valued at approximately $28,000. OFI Invest Asset Management bought a new stake in Lam Research during the 3rd quarter valued at approximately $30,000. Asset Dedication LLC boosted its stake in Lam Research by 56.7% during the 3rd quarter. Asset Dedication LLC now owns 47 shares of the semiconductor company’s stock valued at $30,000 after purchasing an additional 17 shares during the period. Finally, Valued Wealth Advisors LLC bought a new stake in Lam Research during the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Insider Activity at Lam Research

In related news, SVP Seshasayee Varadarajan sold 5,500 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $922.41, for a total value of $5,073,255.00. Following the completion of the sale, the senior vice president now directly owns 22,095 shares in the company, valued at $20,380,648.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Lam Research news, SVP Seshasayee Varadarajan sold 5,500 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $922.41, for a total transaction of $5,073,255.00. Following the completion of the sale, the senior vice president now directly owns 22,095 shares in the company, valued at approximately $20,380,648.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Abhijit Y. Talwalkar sold 882 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $972.03, for a total value of $857,330.46. Following the sale, the director now owns 10,541 shares of the company’s stock, valued at $10,246,168.23. The disclosure for this sale can be found here. Insiders sold 7,029 shares of company stock worth $6,559,489 over the last three months. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Citigroup raised their target price on Lam Research from $800.00 to $975.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. UBS Group raised their target price on Lam Research from $885.00 to $1,130.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Susquehanna raised their price target on Lam Research from $655.00 to $880.00 and gave the company a “neutral” rating in a report on Monday, January 29th. Barclays raised their price target on Lam Research from $750.00 to $825.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Finally, TD Cowen raised their price target on Lam Research from $710.00 to $975.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $931.85.

Lam Research Price Performance

NASDAQ LRCX traded up $17.30 on Tuesday, hitting $885.37. 560,221 shares of the company’s stock were exchanged, compared to its average volume of 1,051,577. The stock has a 50-day moving average of $944.64 and a 200-day moving average of $804.00. The company has a current ratio of 3.06, a quick ratio of 2.02 and a debt-to-equity ratio of 0.61. Lam Research Co. has a 52 week low of $493.42 and a 52 week high of $1,007.39. The stock has a market cap of $116.07 billion, a price-to-earnings ratio of 33.57, a P/E/G ratio of 3.15 and a beta of 1.51.

Lam Research (NASDAQ:LRCX) last announced its quarterly earnings results on Wednesday, January 24th. The semiconductor company reported $7.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.06 by $0.46. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.71 billion. Lam Research had a net margin of 24.15% and a return on equity of 44.47%. The company’s revenue for the quarter was down 28.8% compared to the same quarter last year. During the same period in the prior year, the business earned $10.71 earnings per share. Analysts expect that Lam Research Co. will post 28.92 earnings per share for the current year.

Lam Research Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 3rd. Investors of record on Wednesday, March 13th were issued a $2.00 dividend. The ex-dividend date of this dividend was Tuesday, March 12th. This represents a $8.00 dividend on an annualized basis and a yield of 0.90%. Lam Research’s payout ratio is 30.94%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.